Article Text

Download PDFPDF
Gene expression signature of the ageing lung: breathing new life into COPD
  1. Steven Booth,
  2. Tillie-Louise Hackett
  1. Department of Anesthesiology, Pharmacology and Therapeutics, Centre for Heart Lung Innovation, University of British Columbia, Vancouver, Canada
  1. Correspondence to Dr Tillie-Louise Hackett, Department of Anesthesiology, Pharmacology and Therapeutics, Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC V6T 1Z4, Canada; tillie.hackett{at}hli.ubc.ca

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Due to consistently low birth rates and a higher life expectancy, countries within the European Union are transitioning to a much older population structure.1 The average number of older persons in the total population will increase significantly in the coming decade, as a large proportion of the post-war, baby-boom generation will reach retirement. Compared with generations prior, the ‘baby boomers’ were the most physically fit generation; however, they also grew up when smoking rates and exposure to secondhand smoke were at their peak.2

Tobacco use is a risk factor for six of the eight leading causes of death in the world including respiratory and cardiovascular diseases, stroke and cancer.2 Of these diseases, chronic obstructive pulmonary disease (COPD) is a major growing cause of morbidity and mortality3 with smoking and secondhand smoke exposure being the most important causative factors of the disease.3 In the European Union, the total direct costs of COPD account for 56% (€38.6 billion) of the total healthcare budget. As there is growing evidence that up to 50% of smokers will eventually develop COPD,4–6 the ageing ‘baby-boomer’ population will therefore have a significant effect on future healthcare demands.7

COPD is characterised by irreversible chronic airflow limitation that is caused by emphysematous destruction of lung elastic tissue and obstruction in the small airways due to occlusion of their lumen by inflammatory mucus exudates, narrowing and obliteration. In COPD, the airflow limitation measured by reduced forced expiratory volume in 1 s, progresses very slowly over time—potentially due to the high redundancy of small airway generations.8 9 Therefore, despite symptoms such as cough and phlegm being associated with susceptible smokers aged 20–44 years who will develop COPD, loss of lung function is …

View Full Text

Footnotes

  • Contributors SB and T-LH drafted, reviewed and approved the final version of the manuscript.

  • Funding This study was funded by Canadian Institutes of Health Research (LEKG).

  • Competing interests None declared.

  • Provenance and peer review Commissioned; externally peer reviewed.

Linked Articles

  • Chronic obstructive pulmonary disease
    Maaike de Vries Alen Faiz Roy R Woldhuis Dirkje S Postma Tristan V de Jong Don D Sin Yohan Bossé David C Nickle Victor Guryev Wim Timens Maarten van den Berge Corry-Anke Brandsma